Ownership history in Integrated Advisors Network LLC Β· 5 quarters on record
This page tracks every 13F SEC filing in which Integrated Advisors Network LLC reported a position in CRISPR THERAPEUTICS AG (CRSP). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Integrated Advisors Network LLC underperformed the S&P 500 by β41.2% annually on this CRSP position. Timing score: 33% (1/3 decisions correct). Average cost basis: $66.43. Maximum drawdown during holding period: β20.8%.
β Significantly underperformed the S&P 500 by 41.2% ann.
3 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
1 of 3 add/trim decisions correct
Best entry: $62.60 (2023 Q4) Β· Worst: $68.16 (2024 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
3 adds Β· 2 trims. Bought during 0 of 1 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.01% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size